Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy.

Core Evid · 2016 · PMC4829189 · PMID 27103882

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Adverse effects leading to treatment discontinuation were more likely to occur among patients administered ramipril (4.8%) than those administered azilsartan (3.1%), but this trend did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.